Exelixis | Spese Operative



Operating Expenses Cambiamento Data
Acadia Pharmaceuticals USD 106.1M 112.66M 2024-12
Agios Pharmaceuticals USD 135.77M 1.11B 2024-12
Amgen USD 6.78B 401M 2024-12
AstraZeneca USD 12.86B 2.06B 2024-12
Bayer EUR 8.2B 5.59B 2024-12
BioMarin Pharmaceutical USD 585.91M 45.94M 2024-12
Bristol-Myers Squibb USD 11.55B 1.84B 2024-12
Cytokinetics USD 155.97M 14.7M 2024-12
Eisai JPY 188.58B 7.01B 2024-12
Eli Lilly USD 8.38B 1.53B 2024-12
Exelixis USD 403.55M 82K 2025-01
Genmab DKK 4.25B 812M 2024-12
Glaxosmithkline GBP 7.42B 408M 2024-12
Incyte USD 877.18M 114.6M 2024-12
Ionis Pharmaceuticals USD 337.4M 54.93M 2024-12
MacroGenics USD 56.52M 12.46M 2024-09
Merck USD 11.33B 1.4B 2024-12
Moderna USD 2.21B 280M 2024-12
Neurocrine Biosciences USD 485.7M 47.4M 2024-12
Novartis USD 11.28B 1.73B 2024-12
Pfizer USD 18.17B 5.63B 2024-12
Sanofi EUR 10.52B 1.42B 2024-09
Takeda JPY 1.08T 85.39B 2024-12
Ultragenyx Pharmaceutical USD 287.15M 15.67M 2024-12
Xencor USD 65.97M 7.02M 2024-12



Exelixis Spese Operative - Valori correnti, dati storici, previsioni, statistiche, grafici e calendario economico - Mar 2025.